Literature DB >> 22078465

CYR61 controls p53 and NF-κB expression through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cells.

Kwang-Beom Lee1, Hyun-Jung Byun, Sung Ho Park, Chan-Yong Park, Seung-Hoon Lee, Seung Bae Rho.   

Abstract

CYR61 over-expression promotes cell proliferation by inhibiting carboplatin-induced apoptosis, decreasing Bax expression, and increasing Bcl-xL, Mcl-1, and Bcl-2. At the same time, down-regulating p53 expression, while up-regulated NF-κB expression. Additionally, p21 and p53 promoter activities were reduced, while NF-κB and Bcl-2 activities increased. In parallel, CYR61-expressing cells, during carboplatin-induced apoptosis, resulted in an increase of Akt phosphorylation, while rapamycin-treated cells were not affected. Carboplatin effectively inhibited the activation of mTOR signaling cascade, which includes mTOR, 4E-BP1, p70S6K, HIF-1α, and VEGF. These results provide evidence that CYR61 promotes cell proliferation and inhibits apoptosis.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22078465     DOI: 10.1016/j.canlet.2011.10.016

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  27 in total

1.  MicroRNA-128 promotes proliferation in osteosarcoma cells by downregulating PTEN.

Authors:  Lei Shen; Xiao-Dong Chen; Yao-Hui Zhang
Journal:  Tumour Biol       Date:  2013-10-15

2.  TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.

Authors:  Rachel A Hesler; Jennifer J Huang; Mark D Starr; Victoria M Treboschi; Alyssa G Bernanke; Andrew B Nixon; Shannon J McCall; Rebekah R White; Gerard C Blobe
Journal:  Carcinogenesis       Date:  2016-11-01       Impact factor: 4.944

3.  MicroRNA-100 inhibits osteosarcoma cell proliferation by targeting Cyr61.

Authors:  Jianhua Huang; Kanda Gao; Jian Lin; Qiugen Wang
Journal:  Tumour Biol       Date:  2013-12-10

4.  HDAC5 inactivates CYR61-regulated CD31/mTOR axis to prevent the occurrence of preeclampsia.

Authors:  Peiyue Jiang; Xia Ying; Zhi Li; Ruoan Jiang; Jinling Zhou; Mengmeng Zhang; Xiaofu Yang; Xiaojun Zhu
Journal:  Cell Tissue Res       Date:  2022-07-28       Impact factor: 4.051

5.  The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation.

Authors:  Katarzyna Brodowska; Ahmad Al-Moujahed; Anna Marmalidou; Melissa Meyer Zu Horste; Joanna Cichy; Joan W Miller; Evangelos Gragoudas; Demetrios G Vavvas
Journal:  Exp Eye Res       Date:  2014-05-15       Impact factor: 3.467

6.  Akbu-LAAO exhibits potent anti-tumor activity to HepG2 cells partially through produced H2O2 via TGF-β signal pathway.

Authors:  Chunmei Guo; Shuqing Liu; Panpan Dong; Dongting Zhao; Chengyi Wang; Zhiwei Tao; Ming-Zhong Sun
Journal:  Sci Rep       Date:  2015-12-14       Impact factor: 4.379

7.  Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.

Authors:  Zhi-Qiang Wang; Magdalena Bachvarova; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Dimcho Bachvarov
Journal:  Oncotarget       Date:  2014-01-30

8.  Activation of the mTOR signaling pathway in breast cancer MCF‑7 cells by a peptide derived from Porphyra yezoensis.

Authors:  Su-Jin Park; Jina Ryu; In-Hye Kim; Youn-Hee Choi; Taek-Jeong Nam
Journal:  Oncol Rep       Date:  2014-10-20       Impact factor: 3.906

9.  Oncogene Ras/phosphatidylinositol 3-kinase signaling targets histone H3 acetylation at lysine 56.

Authors:  Yan Liu; Da-Liang Wang; Su Chen; Lei Zhao; Fang-Lin Sun
Journal:  J Biol Chem       Date:  2012-09-16       Impact factor: 5.157

10.  AKT mediates actinomycin D-induced p53 expression.

Authors:  Chih-Shou Chen; Dong-Ru Ho; Fei-Yun Chen; Chang-Rong Chen; Yu-De Ke; Jyan-Gwo Joseph Su
Journal:  Oncotarget       Date:  2014-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.